Ionis Pharmaceuticals, Inc. (IONS) Guidance & Earnings Results
On 2026-07-29 Ionis Pharmaceuticals, Inc. reaffirmed guidance: "TRYNGOLZA $100-110M, DAWNZERA…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IONSIonis Pharmaceuticals, Inc.Follow IONS — free
—
Price chart with a free account
- Market cap
- 7.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Reaffirmed | TRYNGOLZA $100-110M, DAWNZERA $110-120M · full year |
| 29 Apr 26 | Raised | 2026 financial guidance improved; olezarsen peak net sales guidance raised to >$3B from >$2B. · full year |
| 25 Feb 26 | Raised | Exceeded 2025 revenue guidance; 2026 guidance reflects commitment to independent launches · full year |
| 12 Jan 26 | Raised | Olezarsen peak net sales guidance raised to >$2B from >$1B |
| 29 Oct 25 | Raised | Total revenue raised from $825-850M to $875-900M; TRYNGOLZA sales raised from $75-80M to $85-95M; non-GAAP operating loss narrowed from $300-325M to $275-300M · full year |
| 30 Jul 25 | Raised | FY2025 total revenue raised to $825-850M from $725-750M; TRYNGOLZA product sales guided to $75-80M (previously not provided); operating loss on non-GAAP basis improved to $300-325M from <$375M; cash ~$2.0B from ~$1.9B · full year |
Ionis Pharmaceuticals, Inc. — questions
- What guidance did Ionis Pharmaceuticals, Inc. give?
- On 2026-07-29: "TRYNGOLZA $100-110M, DAWNZERA $110-120M"
- When does Ionis Pharmaceuticals, Inc. report earnings?
- Ionis Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-27.
Every figure on this page comes from Ionis Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.